- Home>
- Specialties>
- HIV/AIDS Clinical Care
HIV/AIDS Clinical Care
Stay informed on the changing landscape of HIV care with perspectives on the latest research, antiretroviral alerts, and succinct case discussions from our expert clinicians.
Sign up now for free weekly e-mail alerts featuring the full text of one article and links to new articles on the most clinically relevant research, new guidelines and top news stories in HIV/AIDS Clinical Care.
Featured Article
SUMMARY AND COMMENT
hsCRP Levels and CVD Risk Factors in Patients on ARTFree
- November 16, 2009
- Keith Henry, MD
In a cohort of patients with virologic suppression and low estimated cardiovascular risk, hsCRP levels were elevated and were associated with increased BMI and lipid abnormalities.
- Reviewing:
- Boger MS et al. J Acquir Immune Defic Syndr 2009 Dec; 52:480
Recent HIV/AIDS Clinical Care Articles
SUMMARY AND COMMENT
Rosuvastatin Beats Pravastatin for PI-Associated Hyperlipidemia
- November 16, 2009
- Abigail Zuger, MD
However, the study was small, and patients were followed for only 45 days.
- Reviewing:
- Aslangul E et al. AIDS 2009 Oct 15
SUMMARY AND COMMENT
Immune Activation Persists Despite Effective ARTFree
- November 9, 2009
- Helmut Albrecht, MD
In a cohort of HIV-positive patients, markers of immune activation remained elevated despite 6 years of effective antiretroviral therapy. Immune activation was associated with lower CD4-cell counts.
- Reviewing:
- French MA et al. J Infect Dis 2009 Oct 15; 200:1212
SUMMARY AND COMMENT
Second-Regimen Failure and Mortality Risk
- November 9, 2009
- Keith Henry, MD
Although second-regimen failure and associated mortality declined significantly between 1996/1997 and 2005, the mortality risk remained high.
- Reviewing:
- Deeks SG et al. Clin Infect Dis 2009 Nov 15; 49:1582
SUMMARY AND COMMENT
Influence of HCV Infection on Mortality in HIV-Infected Patients
- November 9, 2009
- Rajesh T. Gandhi, MD
HCV infection is associated with increased overall mortality, but not with AIDS-defining events, in HIV-infected patients.
- Reviewing:
- Chen T-Y et al. Clin Infect Dis 2009 Nov 15; 49:1605
NEWS IN CONTEXT
New CDC Interim Guidance on HIV and H1N1Free
- November 2, 2009
- Carlos del Rio, MD
HIV-infected individuals are a high-priority group for prevention and treatment of 2009 H1N1 influenza.
- Reviewing:
- Centers for Disease Control and Prevention (CDC). 2009 Oct 21
SUMMARY AND COMMENT
Darunavir + Raltegravir + Etravirine = High Rate of Treatment Success
- November 2, 2009
- Paul E. Sax, MD
Ninety percent of highly treatment-experienced patients who received this combination achieved virologic suppression at week 24; results were sustained at week 48.
- Reviewing:
- Yazdanpanah Y et al. Clin Infect Dis 2009 Nov 1; 49:1441
SUMMARY AND COMMENT
Dose Reduction Curbs Efavirenz Toxicity
- November 2, 2009
- Abigail Zuger, MD
Reducing the daily dose of efavirenz to 400 mg or even lower may curb the drug's toxicity without decreasing its effectiveness in patients with high plasma levels.
- Reviewing:
- van Luin M et al. J Acquir Immune Defic Syndr 2009 Oct 1; 52:240
SUMMARY AND COMMENT
Life Expectancy for HIV-Infected Patients in the U.S.
- November 2, 2009
- Sonia Nagy Chimienti, MD
Average life expectancy continues to improve, but disparities persist.
- Reviewing:
- Harrison KM et al. J Acquir Immune Defic Syndr 2009 Sep 2
SUMMARY AND COMMENT
No Increase in Transmitted HIV-Drug Resistance in Europe
- November 2, 2009
- Charles B. Hicks, MD
Between 2002 and 2006, the rates of transmitted drug resistance in Europe stabilized at <10%. Possible reasons abound.
- Reviewing:
- Vercauteren J et al. J Infect Dis 2009 Nov 15; 200:1503
SUMMARY AND COMMENT
A Glimmer of Hope for HIV VaccinesFree
- October 22, 2009
- Frances H. Priddy, MD, MPH, and Carlos del Rio, MD
A large trial has shown that a vaccine can protect against HIV acquisition. The task now is to figure out how to build on this initial success.
- Reviewing:
- Rerks-Ngarm S et al. N Engl J Med 2009 Oct 20
Editor's Picks from across Journal Watch
SUMMARY AND COMMENT
N95 Respirators or Surgical Mask for Protection from Influenza?
- November 6, 2009
- By Kristi L. Koenig, MD, FACEP
- Emergency Medicine
By current knowledge, a surgical mask is sufficient. Save N95 respirators for TB and other aerosol-transmitted diseases.
- Reviewing:
- Crit Care Med 2009 Sep 1
DRUG WATCH
Peramivir for Treatment of 2009 H1N1 Influenza
- November 4, 2009
- By Lynn Estes, PharmD
- Infectious Diseases
Responding to a CDC request, the FDA authorized the emergency use of this investigational agent in critically ill patients.
- Reviewing:
- 2009 Oct 24
SUMMARY AND COMMENT
Immune Response from Bronchoalveolar Lavage Mononuclear Cells Diagnoses Active TB
- October 21, 2009
- By Neil M. Ampel, MD
- Infectious Diseases
ELISpot performed on bronchoalveolar mononuclear cells had a sensitivity of 91% and a specificity of 79% in diagnosing active disease.
- Reviewing:
- Am J Respir Crit Care Med 2009 Oct 1; 180:666
SUMMARY AND COMMENT
Surgical Masks or N95 Respirators for the Flu?Free
- October 21, 2009
- By Richard T. Ellison III, MD
- Infectious Diseases
In a randomized trial, surgical masks and N95 respirators provided healthcare workers with comparable protection against influenza.
- Reviewing:
- JAMA 2009 Oct 1
Jounal Watch HIV/AIDS Clinical Care summarizes important medical journal articles about a wide variety of HIV-related subjects including acute HIV infection, antiretroviral resistance, epidemiology, hepatitis, initial therapy, medication adherence, opportunistic infections, and STDs.
